banner
JAK inhibitor Ruxolitinib phosphate, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ413

JAK inhibitor Ruxolitinib phosphate, Purity ≥98%

Synonym: Ruxolitinib phosphate; 1092939-17-7; Jakafi; Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; OPZELURA; Ruxolitinib (phosphate); JAK inhibitor

  • MDL: MFCD18452860
  • CAS Number: 1092939-17-7
  • Compound CID: 25127112
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
Ruxolitinib phosphate, soluble in DMSO, water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, and Tyk2.
Molecular Weight
404.37
Molecular Formula
C17H21N6O4P
Targets
JAK1: 3.3 nM; JAK2: 2.8 nM; JAK3: 428 nM; Tyk2: 19 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 73 mg/mL (180.53 mM); Water: 26 mg/mL (64.29 mM); Ethanol: 7 mg/mL (17.31 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
Ruxolitinib phosphate is used to study JAK1 and JAK2 selective inhibition.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0